MPH Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.88 |
| 52 Week High | CA$1.59 |
| 52 Week Low | CA$0.84 |
| Beta | 0.87 |
| 11 Month Change | 0% |
| 3 Month Change | -17.76% |
| 1 Year Change | -45.68% |
| 33 Year Change | -12.00% |
| 5 Year Change | -82.29% |
| Change since IPO | -91.85% |
Recent News & Updates
Recent updates
Medicure Inc.'s (CVE:MPH) Price Is Right But Growth Is Lacking
Jul 31
Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Shareholder Returns
| MPH | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -11.1% | -13.2% | -0.7% |
| 1Y | -45.7% | -8.5% | 20.2% |
Return vs Industry: MPH underperformed the Canadian Biotechs industry which returned -8.1% over the past year.
Return vs Market: MPH underperformed the Canadian Market which returned 20.4% over the past year.
Price Volatility
| MPH volatility | |
|---|---|
| MPH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MPH's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine MPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| MPH fundamental statistics | |
|---|---|
| Market cap | CA$9.18m |
| Earnings (TTM) | -CA$2.63m |
| Revenue (TTM) | CA$20.93m |
0.4x
P/S Ratio-3.5x
P/E RatioIs MPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPH income statement (TTM) | |
|---|---|
| Revenue | CA$20.93m |
| Cost of Revenue | CA$8.08m |
| Gross Profit | CA$12.85m |
| Other Expenses | CA$15.48m |
| Earnings | -CA$2.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 61.41% |
| Net Profit Margin | -12.56% |
| Debt/Equity Ratio | 0% |
How did MPH perform over the long term?
See historical performance and comparison